Endosense Underscores Significance of Contact Force Parameters With New Study Data at Heart Rhythm 2013
5/13/2013 11:19:20 AM
More...
|
Endosense Closes an Additional USD 4.3 Million/CHF 4 Million in Series C Financing
3/5/2013 10:02:48 AM
More...
|
First U.S. Case Performed With Endosense’s TactiCath® Quartz Contact-Force Sensing Ablation Catheter
2/1/2013 9:15:10 AM
More...
|
Endosense Appoints Nicolas Marsault as New Chief Financial Officer
12/6/2012 11:56:09 AM
More...
|
Endosense Secures $40.3 Million Series C Financing
11/27/2012 7:18:34 AM
More...
|
Endosense Completes Enrollment in TOCCASTAR IDE Study of Its TactiCath® Force-Sensing Ablation Catheter
6/13/2012 10:41:40 AM
More...
|
Endosense and BIOTRONIK Announce CE Mark Approval, First Clinical Use of the New TactiCath(R) Quartz Force-Sensing Ablation Catheter
6/12/2012 8:00:22 AM
More...
|
Endosense Reports Strong Momentum for Contact-Force Sensing in Catheter Ablation at Heart Rhythm 2012
5/14/2012 9:53:20 AM
More...
|
Endosense Launches TactiCath® 75 Force-Sensing Catheter, Announces New Results of EFFICAS I Clinical Study
1/12/2012 6:56:48 AM
More...
|
Endosense Names Jan Keltjens President and Chief Executive Officer
9/14/2011 7:22:24 AM
More...
|
|